慢性髓细胞白血病BCR／ABL1突变克隆演化和治疗策略  

Chronic myeloid leukemia BCR/ABL1 mutation clonal evolution and treatment strategies

作　　者：朱平[1] 

机构地区：[1]北京航天总医院血液·肿瘤研究所,100076

出　　处：《中华检验医学杂志》2012年第1期2-5,共4页Chinese Journal of Laboratory Medicine

基　　金：基金项目：国家863高技术研究发展计划资助项目（2008AA062503）

摘　　要：伊马替尼的应用使很多慢性髓细胞白血病（chronic myeloid leukemia,CML）患者获得了长期生存,但是CML的BCR-ABL1融合基因激酶区突变（kinase domain mutation,KDM）会造成耐药.KDM有多种类型,不同类型是随机出现的.带有不同KDM特征的白血病克隆有一定的演变规律.在伊马替尼用药期间,耐药程度较高的突变细胞容易发展为优势克隆.建议在治疗伊马替尼耐药的CML时,除了努力发展下一代酪氨酸激酶抑制剂以外,还可考虑用传统药物来辅助治疗.Application of imatinib has made a lot of chronic myeloid leukemia （CML） patients longterm survival,but the CML BCR/ABL1 kinase domain mutations （KDM） will result in drug resistance of imatinib.There are many KDM types.The different types appear randomly.The leukemic clone with different KDM characteristics has a certain evolution.In the period of imatinib treatment,a higher degree of drug resistance mutations in cells likely to develop as the dominant clone.It is suggested that the treatment of imatinib-resistant CML in addition to efforts to develop next-generation tyrosine kinase inhibitors outside,but also consider the use of traditional medicine to help cure.

关 键 词：白血病 髓系 慢性 融合蛋白质类 bcr-abl 哌嗪类 嘧啶类 蛋白酪氨酸激 酶类 突变 

分 类 号：R733.72[医药卫生—肿瘤]